Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study
暂无分享,去创建一个
Paul M. Grasby | Mitul A. Mehta | Oliver D. Howes | Paul R. A. Stokes | Alice Egerton | Julia M. Lappin | Suzanne J. Reeves | John P. Shotbolt | Ella Hirani | Rabia Ahmad | A. Egerton | S. Reeves | P. Grasby | O. Howes | M. Mehta | J. Lappin | P. Stokes | R. Ahmad | E. Hirani | J. Shotbolt
[1] D. D. Bois,et al. CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .
[2] Karmen K. Yoder,et al. What were they thinking? Cognitive states may influence [11C]raclopride binding potential in the striatum , 2008, Neuroscience Letters.
[3] D L Alexoff,et al. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine , 2006, Synapse.
[4] T. Cooper,et al. Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. , 1986, Drug metabolism and disposition: the biological fate of chemicals.
[5] H. Aubin. Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation , 2012, Drugs.
[6] M. Daube-Witherspoon,et al. Quantitative functional brain imaging with positron emission tomography , 1998 .
[7] D. Balfour,et al. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell , 2007, The European journal of neuroscience.
[8] A. Yacobi,et al. Toxicokinetics and New Drug Development , 1989 .
[9] Ralph Myers,et al. Small animal PET , 2002, European Neuropsychopharmacology.
[10] D. Schroeder,et al. A comparison of sustained-release bupropion and placebo for smoking cessation. , 1997, The New England journal of medicine.
[11] J. Swanson,et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications , 2002, Synapse.
[12] N. Panagopoulos,et al. Dopaminergic innervation and binding in the rat cerebellum , 1991, Neuroscience Letters.
[13] D. H. Schroeder. Metabolism and kinetics of bupropion. , 1983, The Journal of clinical psychiatry.
[14] S. Haber,et al. Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] M. Laruelle. Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[16] D. Wong,et al. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats , 2002, Neuropharmacology.
[17] A. Tanács,et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. , 2005, Journal of affective disorders.
[18] Alexander Hammers,et al. Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.
[19] H. Fibiger,et al. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[20] L. Dwoskin,et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. , 2006, CNS drug reviews.
[21] Aker,et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.
[22] Colin Studholme,et al. Automated 3-D registration of MR and CT images of the head , 1996, Medical Image Anal..
[23] Stephen A. Williams,et al. Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration , 2003, Neuropsychopharmacology.
[24] Ralph Myers,et al. Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.
[25] Adriaan A. Lammertsma,et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease , 1996, Journal of Neuroscience Methods.
[26] J. Feighner,et al. Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.
[27] R. Lukas,et al. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. , 1999, The Journal of pharmacology and experimental therapeutics.
[28] N. Paterson. Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. , 2009, European journal of pharmacology.
[29] S. Andersen,et al. The effects of bupropion in vivo in the neostriatum of 5-day-old and adult rats. , 1997, Brain research. Developmental brain research.
[30] Alan A. Wilson,et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment , 2002, Psychopharmacology.
[31] R Myers,et al. Effect of 5‐HT on binding of [11C] WAY 100635 to 5‐HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine , 2001, Synapse.
[32] David J. Brooks,et al. Measuring Neurotransmitter Release with PET: Methodological Issues , 1998 .
[33] J. A. Johnston,et al. Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers , 1997, Journal of clinical pharmacology.
[34] H. Fibiger,et al. Interstitial 3‐Methoxytyramine Reflects Striatal Dopamine Release: An In Vivo Microdialysis Study , 1991, Journal of neurochemistry.
[35] M. Shoaib,et al. How does bupropion work as a smoking cessation aid? , 2005, Addiction biology.
[36] A. Egerton,et al. Dopamine Release in the Human Striatum: Motor and Cognitive Tasks Revisited , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[38] K. Johnson-Davis,et al. Bupropion increases striatal vesicular monoamine transport , 2005, Neuropharmacology.
[39] L. Dwoskin,et al. Bupropion Inhibits Nicotine-Evoked [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine and from Rat Hippocampal Slices Preloaded with [3H]Norepinephrine , 2002, Journal of Pharmacology and Experimental Therapeutics.
[40] R A Robb,et al. A software system for interactive and quantitative visualization of multidimensional biomedical images. , 1991, Australasian physical & engineering sciences in medicine.
[41] S. Shiffman,et al. The effect of bupropion on nicotine craving and withdrawal , 2000, Psychopharmacology.
[42] M. Bergström,et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography , 2003, Biological Psychiatry.
[43] Osama Mawlawi,et al. Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[44] Walter Ling,et al. Bupropion for the Treatment of Methamphetamine Dependence , 2008, Neuropsychopharmacology.
[45] A. Owen. Cognitive planning in humans: Neuropsychological, neuroanatomical and neuropharmacological perspectives , 1997, Progress in Neurobiology.
[46] J. Costentin,et al. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission , 2007, British journal of pharmacology.
[47] N. Harada,et al. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [ 11 C ]raclopride?: PET studies combined with microdialysis in conscious monkeys , 1999, Brain Research.
[48] R. Lukas,et al. Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors , 2004, Molecular Pharmacology.
[49] Gerome Breen,et al. Can recreational doses of THC produce significant dopamine release in the human striatum? , 2009, NeuroImage.
[50] Ella Hirani,et al. Temporal characterisation of amphetamine‐induced dopamine release assessed with [11C]raclopride in anaesthetised rodents , 2004, Synapse.
[51] P. Dannon,et al. Sustained-release Bupropion Versus Naltrexone in the Treatment of Pathological Gambling: A Preliminary Blind-rater Study , 2005, Journal of clinical psychopharmacology.
[52] S. Wonnacott,et al. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. , 2007, Biochemical pharmacology.
[53] R. Ferris,et al. Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β-adrenergic, serotonergic (5-HT2), α 2-adrenergic, imipramine and dopaminergic receptors in brain , 1983, Neuropharmacology.
[54] F E Turkheimer,et al. Multiresolution Analysis of Emission Tomography Images in the Wavelet Domain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[55] N. Volkow,et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects , 2005, Biological Psychiatry.
[56] D. DuBois,et al. A formula to estimate the approximate surface area if height and weight be known , 1989 .
[57] M. Damaj,et al. Bupropion is a nicotinic antagonist. , 2000, The Journal of pharmacology and experimental therapeutics.